Abstract
Recent innovations in ADC design and innate immune modulation reveal complementary therapeutic strategies for cancer and inflammatory diseases. Novel hydrophilic multivalent linkers enable very high drug-to-antibody ratios and dual-payload ADCs, while modulation of MDAS, TLR7, TLR5, and STING pathways induces p16(+) immune subsets that promote disease tolerance. Together, these inventions highlight convergent mechanisms for improving efficacy, resilience, and therapeutic durability.